Does it work in childhood and adolescence? The predictive role of postoperative/preablative stimulated thyroglobulin levels in paediatric thyroid cancer. A systematic review of the literature.
Iodine
Paediatric
Post-operative
Preablative
Thyroglobulin
Thyroid
Thyroid cancer
Journal
Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
accepted:
01
09
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
24
9
2023
Statut:
aheadofprint
Résumé
Thyroglobulin is a well-established disease marker during follow-up in paediatric differentiated thyroid cancer. However, no conclusive data on the role of endogenously stimulated thyroglobulin after thyroidectomy (ptTg) in predicting disease-specific outcomes are available. This review aims to establish the prognostic value of ptTg in children with DTC. Online medical databases were searched for studies evaluating the association between ptTg and disease-specific outcomes in DTC-affected children. Documents not in English, preclinical studies, other review articles, case reports, and small case series were excluded. The risk of bias was assessed with the QUADAS-2 tool. Twelve studies, analysing 1043 children in total, were included in the review. They all had a retrospective design and were published between 2016 and 2022. Of all patients, 1008 (97%) and 849 (81%) had undergone thyroidectomy and RAI, respectively. Eight studies (756 children) evaluated the correlation between ptTg and disease persistence/relapse: six reported a significant association between these parameters; a specific ptTg cut-off (10-14 ng/ml) was identified at the multivariate analysis in three studies. The remaining four studies assessed the link between ptTg levels and disease extension, with three reporting a correlation between ptTg and lung/nodal metastases. ptTg is a readily available and inexpensive parameter, bearing a strong prognostic power in identifying disease persistence, relapse, and the presence of metastases in children affected by DTC.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroglobulin is a well-established disease marker during follow-up in paediatric differentiated thyroid cancer. However, no conclusive data on the role of endogenously stimulated thyroglobulin after thyroidectomy (ptTg) in predicting disease-specific outcomes are available. This review aims to establish the prognostic value of ptTg in children with DTC.
METHODS
METHODS
Online medical databases were searched for studies evaluating the association between ptTg and disease-specific outcomes in DTC-affected children. Documents not in English, preclinical studies, other review articles, case reports, and small case series were excluded. The risk of bias was assessed with the QUADAS-2 tool.
RESULTS
RESULTS
Twelve studies, analysing 1043 children in total, were included in the review. They all had a retrospective design and were published between 2016 and 2022. Of all patients, 1008 (97%) and 849 (81%) had undergone thyroidectomy and RAI, respectively. Eight studies (756 children) evaluated the correlation between ptTg and disease persistence/relapse: six reported a significant association between these parameters; a specific ptTg cut-off (10-14 ng/ml) was identified at the multivariate analysis in three studies. The remaining four studies assessed the link between ptTg levels and disease extension, with three reporting a correlation between ptTg and lung/nodal metastases.
DISCUSSION
CONCLUSIONS
ptTg is a readily available and inexpensive parameter, bearing a strong prognostic power in identifying disease persistence, relapse, and the presence of metastases in children affected by DTC.
Identifiants
pubmed: 37743443
doi: 10.1007/s11154-023-09835-z
pii: 10.1007/s11154-023-09835-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64.
Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L et al. 2022 european thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022;11.
Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM et al. Management guidelines for children with thyroid nodules and differentiated thyroid Cancer. Thyroid. 2015;25.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al. 2015 american thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the american thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid Cancer. Thyroid 2016;26.
Tae YK, Won BK, Eun SK, Jin SR, Jeong SY, Seong CK et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90.
Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med. 2013;38.
Piccardo A, Siri G, Ugolini M, Fiz F, Puntoni M, Bottoni G et al. A three-domain scoring system to customize the risk of relapse of differentiated thyroid carcinoma. Cancers (Basel). 2021;13.
Piccardo A, Siri G, Raffa S, Castellana M, Foppiani L, Bottoni G et al. How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender. Eur J Nucl Med Mol Imaging. 2020.
Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, Burch HB. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;9:2754–63.
doi: 10.1210/jc.2012-1533
Souza Do Rosário PW, Guimarães VC, Ribeiro Maia FF, Fagundes TA, Purisch S, Padrao EL et al. Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope. 2005;115.
Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A et al. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer - is there a need for radioactive iodine therapy? Surg (United States). 2012;152.
Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, Witterick IJ et al. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine. 2015;50.
Li S, Ren C, Gong Y, Ye F, Tang Y, Xu J et al. The role of Thyroglobulin in Preoperative and postoperative evaluation of patients with differentiated thyroid Cancer. Front Endocrinol (Lausanne). 2022.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al. Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011.
Lazar L, Lebenthal Y, Segal K, Steinmetz A, Strenov Y, Cohen M, Yaniv I, Yackobovitch-Gavan M, Phillip M. Pediatric thyroid Cancer: postoperative classifications and response to initial therapy as prognostic factors. J Clin Endocrinol Metab. 2016;101:1970–9.
doi: 10.1210/jc.2015-3960
pubmed: 26930182
Livhits MJ, Pasternak JD, Xiong M, Li N, Gosnell JE, Yeh MW, Chiu HK, PRE-ABLATION THYROGLOBULIN, AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER. Endocr Pract. 2016;22:1259–66.
doi: 10.4158/EP161360.OR
pubmed: 27482611
Zanella A, Scheffel RS, Pasa MW, Dora JM, Maia AL. Role of postoperative stimulated thyroglobulin as prognostic factor for differentiated thyroid Cancer in children and adolescents. Thyroid. 2017;27:787–92.
doi: 10.1089/thy.2016.0559
pubmed: 28292215
Liu L, Huang F, Liu B, Huang R. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin. J Pediatr Endocrinol Metab. 2018;26:31:751–6.
doi: 10.1515/jpem-2018-0075
Byeon HK, Kim SB, Oh HS, Kim HK, Choi IH, Kim H, Cho JG, Oh KH, Baek SK, Woo JS, Kwon SY, Kim HY, Jung KY. Clinical analysis of Pediatric thyroid Cancer: a single Medical Institution experience of 18 years. Ann Otol Rhinol Laryngol. 2019;128(12):1152–7.
doi: 10.1177/0003489419868251
pubmed: 31375033
Prpić M, Franceschi M, Jukić T, Kust D, Dabelić N, Varjačić T, Lucijanić M, Bolanča A, Kusić Z. DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤ 18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131). Acta Clin Croat. 2019;58(1):119–27.
pubmed: 31363334
pmcid: 6629190
Liu L, Zhang X, Tian T, Huang R, Liu B. Prognostic value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with differentiated thyroid Cancer. Thyroid. 2020;30(7):1017–24.
doi: 10.1089/thy.2019.0585
pubmed: 31964278
Karapanou O, Tzanela M, Rondogianni P, Dacou-Voutetakis C, Chiotis D, Vlassopoulou B, Vassiliadi D, Kanaka-Gantenbein C, Tsagarakis S. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence. Endocrine. 2020;70(3):566–74.
doi: 10.1007/s12020-020-02378-2
pubmed: 32533509
Chesover AD, Vali R, Hemmati SH, Wasserman JD. Lung metastasis in children with differentiated thyroid Cancer: factors Associated with diagnosis and outcomes of Therapy. Thyroid. 2021;31(1):50–60.
doi: 10.1089/thy.2020.0002
pubmed: 32517539
Tian T, Jiang L, Zhang X, Huang R, Liu B. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer. Surgery. 2020;168:1095–100.
doi: 10.1016/j.surg.2020.07.058
pubmed: 32948335
Klain M, Zampella E, Manganelli M, Gaudieri V, Nappi C, D’Antonio A, Piscopo L, Volpe F, Pace L, Schlumberger M, Cuocolo A. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine. 2021;71(2):378–84.
doi: 10.1007/s12020-020-02379-1
pubmed: 32529282
Cistaro A, Quartuccio N, Garganese MC, Villani MF, Altini C, Pizzoferro M, Piccardo A, Cabria M, Massollo M, Maghnie M, Campennì A, Siracusa M, Baldari S, Panareo S, Urso L, Bartolomei M, De Palma D, Mazzoletti A, Dondi A, Bertagna F, Giubbini F, Albano R. D.
Enomoto Y, Enomoto K, Uchino S, Shibuya H, Watanabe S, Noguchi S. Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure. World J Surg. 2012;36:1241–6.
doi: 10.1007/s00268-012-1558-4
pubmed: 22411092
Palmer BA, Zarroug AE, Poley RN, Kollars JP, Moir CR. Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence. J Pediatr Surg. 2005;40:1284–8.
doi: 10.1016/j.jpedsurg.2005.05.012
pubmed: 16080933